Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension

Zhou, Dansha1; Liu, Chunli1; Wang, Lan2; Li, Jifeng3; Zhao, Yating4; Deng, Zheng5; Hou, Chi1,6; Fu, Yingyun7,8; Jiang, Qian1; Lai, Ning1; Zhang, Rui2; Feng, Weici1; Gao, Chuhui1; Li, Xiang1; Jiang, Mei1; Fu, Xin9; Chen, Jiyuan1; Hong, Wei1,9; Xu, Lei10; He, Wenjun1; Liu, Jinming2; Yang, Yuanhua3; Lu, Wenju1; Zhong, Nanshan1; Cao, Yunshan4,11; Wang, Jian1,12,13,14; Chen, Yuqin1,13,14

2024-06-01

10.1002/ctm2.1702

CLINICAL AND TRANSLATIONAL MEDICINE   影响因子和分区

2001-1326

BackgroundPatients with pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD) have an increased risk of disease exacerbation and decreased survival. We aimed to develop and validate a non-invasive nomogram for predicting COPD associated with severe PH and a prognostic nomogram for patients with COPD and concurrent PH (COPD-PH). MethodsThis study included 535 patients with COPD-PH from six hospitals. A multivariate logistic regression analysis was used to analyse the risk factors for severe PH in patients with COPD and a multivariate Cox regression was used for the prognostic factors of COPD-PH. Performance was assessed using calibration, the area under the receiver operating characteristic curve and decision analysis curves. Kaplan-Meier curves were used for a survival analysis. The nomograms were developed as online network software. ResultsTricuspid regurgitation velocity, right ventricular diameter, N-terminal pro-brain natriuretic peptide (NT-proBNP), the red blood cell count, New York Heart Association functional class and sex were non-invasive independent variables of severe PH in patients with COPD. These variables were used to construct a risk assessment nomogram with good discrimination. NT-proBNP, mean pulmonary arterial pressure, partial pressure of arterial oxygen, the platelet count and albumin were independent prognostic factors for COPD-PH and were used to create a predictive nomogram of overall survival rates. ConclusionsThe proposed nomograms based on a large sample size of patients with COPD-PH could be used as non-invasive clinical tools to enhance the risk assessment of severe PH in patients with COPD and for the prognosis of COPD-PH. Additionally, the online network has the potential to provide artificial intelligence-assisted diagnosis and treatment.

COPD nomogram pulmonary hypertension survival

SCI

英语

其他

National Key R&D Program of China["2022YFE0131500","2016YFC1304102","2018YFC1311900"] ; R&D Program of Guangzhou National Laboratory[GZNL2023A02013] ; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program[2017BT01S155] ; Guangdong Department of Science and Technology["2024A1515011208","2023A1515010443","2022A1515012052"] ; Basic Science and Application of Guangzhou Science and Technology Plan["202201010069","202102020019"] ; Guangzhou Municipal Science and Technology Bureau Guangzhou Key Research and Development Program[2023B03J1387] ; Guangzhou Municipal Science and Technology Bureau Municipal Schools (Institutes)[202201020401] ; Independent Project of State Key Laboratory of Respiratory Disease["SKLRD-Z-202101","SKLRD-Z-202313","YKD2021MS003"] ; Project of Shanghai Pulmonary Hospital Clinical Research[FKLY 20005] ; Reform and Development Program of Beijing Institute of Respiratory Medicine[2022-03] ; Open Research Funds from The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)[202201-101] ; Key Laboratory Development Projects of Department of Science and Technology of Yunnan Province[2017ZDKFKTO02] ; Guangzhou Medical University Student Innovation Enhancement Program[01-408-2201096] ; null[82370063] ; null[82170069] ; null[82120108001] ; null[82241012] ; null[8224100322] ; null[82000045]

Oncology ; Research & Experimental Medicine

Oncology ; Medicine, Research & Experimental

WOS:001244292800001

JOHN WILEY & SONS LTD

Web of Science

1.Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis, Natl Ctr Resp Med,Affiliated Hosp 1,State Key Lab, Guangzhou, Guangdong, Peoples R China
2.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pulm Circulat, Shanghai, Peoples R China
3.Capital Med Univ, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China
4.Gansu Prov Hosp, Dept Cardiol, Lanzhou, Gansu, Peoples R China
5.First Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China
6.Guangzhou Women & Childrens Med Ctr, Dept Neurol, Guangzhou, Guangdong, Peoples R China
7.Jinan Univ, Shenzhen Peoples Hosp, Shenzhen Inst Resp Dis, Clin Med Coll 2,Dept Pulm & Crit Care Med,Shenzhen, Shenzhen, Guangdong, Peoples R China
8.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
9.Guangzhou Med Univ, GMU GIBH Joint Sch Life Sci, Guangzhou, Guangdong, Peoples R China
10.Inner Mongolia Med Univ, Affiliated Hosp, Dept Pulm & Crit Care Med, Hohhot, Peoples R China
11.Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Heart Lung & Vessels Ctr, Chengdu 610072, Sichuan, Peoples R China
12.Guangzhou Int Bio Isl, Guangzhou Lab, Guangzhou, Guangdong, Peoples R China
13.Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, Sect Physiol, La Jolla, CA USA
14.Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Ctr Resp Med, Natl Clin Res Ctr Resp Dis,Affiliated Hosp 1,State, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China

Zhou, Dansha,Liu, Chunli,Wang, Lan,et al. Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension[J]. CLINICAL AND TRANSLATIONAL MEDICINE,2024,14(6).

Zhou, Dansha.,Liu, Chunli.,Wang, Lan.,Li, Jifeng.,Zhao, Yating.,...&Chen, Yuqin.(2024).Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension.CLINICAL AND TRANSLATIONAL MEDICINE,14(6).

Zhou, Dansha,et al."Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension".CLINICAL AND TRANSLATIONAL MEDICINE 14.6(2024).